NXP900 yielded positive data in a preclinical xenograft model of group 4 medulloblastoma.
Merck announced positive topline results from the pivotal phase III MK-3475A-D77 trial.
NXP900 show promise in preclinical model of group 4 medulloblastoma
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Researchers at City of Hope found that taking white button mushroom pills reduces a class of immune cells called myeloid-derived suppressor cells, which has been linked to cancer development and spread.
In a phase II clinical trial, a research team led by Nilofer Azad, professor of oncology and co-leader of the Kimmel Cancer Center’s Cancer Genetics and Epigenetics Program, and Marina Baretti, the Jiasheng Chair in Hepato-Biliary Cancer at the Kimmel Cancer Center, tested the safety and efficacy of the combination of two drugs: an immunotherapy, nivolumab, and an epigenetic drug, entinostat—a histone deacetylase inhibitor.
A group of investigators led by Cedars-Sinai have developed and successfully tested a new artificial intelligence method to make launching cancer clinical trials easier and faster. The method uses patients’ pathology reports to automate the classification of patients by the severity of their cancers, potentially shortening the process of selecting candidates for clinical trials.
Immunai Inc. announced a multi-year collaboration with Teva Pharmaceuticals, an affiliate of Teva Pharmaceutical Industries Ltd. Under the agreement, Immunai will collaborate with Teva in immunology and Immuno-oncology programs.
J. Leonard Lichtenfeld joined SpotitEarly, an Israel-based technology company transforming cancer screening by harnessing the power of artificial intelligence and dogs to detect cancer early, as chief medical officer.
